ClinicalTrials.gg

Program

ISL/ULO

A development code.

Its studies are mostly in Infections, led by Merck.

Furthest: phase 3, since Dec 1, 20251 company-led study, 1 open or runningNext primary completion: Feb 1, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck11 open or runningphase 3since Dec 1, 2025Dec 1, 2025Feb 1, 2029phase 3 · NCT07266831
  • Named in Merck’s own pipeline as islatravir + lenacapavir (MK-8591D), phase 3, as of Nov 2, 2026 (source).
  • Named in Merck’s own pipeline as islatravir + ulonivirine (MK-8591B), phase 2, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2025First study: phase 3 study in Acquired Immunodeficiency SyndromeFirst studyNCT07266831 · 570 planned · United States, Argentina, Canada and more

Ahead

  1. Feb 1, 2029Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07266831

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07266831Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more3RecruitingFeb 1, 2029570

How it is read

Names in the registry

  • “ISL/ULO”, 1 entry

Codes read as this program: MK8591B.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ISL/ULO (Merck): development program | ClinicalTrials.gg